BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/12/2018 11:58:04 AM | Browse: 1508 | Download: 2603
Publication Name World Journal of Diabetes
Manuscript ID 40441
Country Japan
ISSN 1948-9358 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology & Metabolism
Manuscript Type Retrospective Cohort Study
Article Title Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study
Manuscript Source Invited Manuscript
All Author List Hidetaka Hamasaki and Yasuteru Hamasaki
ORCID
Author(s) ORCID Number
Hidetaka Hamasaki http://orcid.org/0000-0002-0124-597X
Yasuteru Hamasaki http://orcid.org/0000-0002-1522-0132
Funding Agency and Grant Number
Corresponding Author Hidetaka Hamasaki, MD, PhD, Doctor, Doctor, Endocrinology and Metabolism, Internal Medicine, Hamasaki Clinic, 2-21-4 Nishida, Kagoshima 8900046, Japan. hhamasaki78@gmail.com
Key Words Type 2 diabetes mellitus; Dipeptidyl pep­tidase-4 inhibitor; Anagliptin; Linagliptin; Cholesterol
Core Tip Whether a substantial clinical difference exists in the effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters remains inconclusive. Although this study is a relatively small-scale, short duration, retrospective study, the findings of this study suggests that the efficacy of DPP-4 inhibitors on the blood pressure, lipid profile, and liver function differs between anagliptin and linagliptin.
Publish Date 2018-10-12 11:58
Citation Hamasaki H, Hamasaki Y. Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study. World J Diabetes 2018; 9(10): 165-171
URL http://www.wjgnet.com/1948-9358/full/v9/i10/165.htm
DOI http://dx.doi.org/10.4239/wjd.v9.i10.165
Full Article (PDF) WJD-9-165.pdf
Full Article (Word) WJD-9-165.doc